The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal
Status Awaiting development
Process STA 2018
ID number 3758

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
30 November 2020 Following the written consultation on the draft remit and scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel (TSOP) in October 2020. The report included advice and recommendations to aid the decision-making process. TSOP concluded that an appraisal of remimazolam for sedation for people having diagnostic or therapeutic procedures was not appropriate. This means the technology in this indication will not be appraised by NICE.
05 October 2020 (10:00) Scoping workshop
18 August 2020 - 16 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual